Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Carl Regillo, MD
Principal Investigator
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
68 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Clinical Site 201
Arecibo, Puerto Rico
- Clinical Site 123
Peoria, Arizona, United States
- Clinical Site 150
Phoenix, Arizona, United States
- Clinical Site 111
Beverly Hills, California, United States
- Clinical Site 113
Encino, California, United States
- Clinical Site 138
Fresno, California, United States
- Clinical Site 129
Huntington Beach, California, United States
- Clinical Site 121
Pasadena, California, United States
- Clinical Site 127
Pasadena, California, United States
- Clinical Site 142
Rancho Cordova, California, United States
- Clinical Site 116
Riverside, California, United States
- Clinical Site 125
Sacramento, California, United States
- Cincor Site 171
Torrance, California, United States
- Clinical Site 160
Walnut Creek, California, United States
- Clinical Site 157
Coral Springs, Florida, United States
- Clinical Site 106
Fort Lauderdale, Florida, United States
- Clinical Site 131
Jacksonville, Florida, United States
- Clinical Site 110
Miami, Florida, United States
- Clinical Site 153
St. Petersburg, Florida, United States
- Clinical Site 117
Winter Haven, Florida, United States
- Clinical Site 112
‘Aiea, Hawaii, United States
- Clinical Site 146
Oak Forest, Illinois, United States
- Clinical Site 128
Springfield, Illinois, United States
- Clinical Site 154
Indianapolis, Indiana, United States
- Clinical Site 139
Lenexa, Kansas, United States
- Clinical Site 166
Louisville, Kentucky, United States
- Clinical Site 167
Metairie, Louisiana, United States
- Clinical Site 145
Baltimore, Maryland, United States
- Clinical Site 163
Baltimore, Maryland, United States
- Clinical Site 103
Hagerstown, Maryland, United States
- Clinical Site 104
Boston, Massachusetts, United States
- Clinical Site 151
Boston, Massachusetts, United States
- Clinical Site 141
Detroit, Michigan, United States
- Clinical Site 155
Southaven, Mississippi, United States
- Clinical Site 101
Reno, Nevada, United States
- Clinical Site 105
Bloomfield, New Jersey, United States
- Clinical Site 136
Cherry Hill, New Jersey, United States
- Clinical Site 114
Teaneck, New Jersey, United States
- Clinical Site 118
Albuquerque, New Mexico, United States
- Clinical Site 109
Liverpool, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Jul 2022
- Primary completion
- 29 Dec 2023
- Completion
- 29 Dec 2023
- Last update posted
- 9 Aug 2024
- Registered enrollment
- 225
- Registry id
- NCT05409235
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.